Ignyta, Inc.
(NASDAQ : RXDX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.01%105.151.1%$1271.29m
GILDGilead Sciences, Inc.
0.12%72.910.9%$642.37m
AMGNAmgen Inc.
0.32%170.501.1%$479.46m
REGNRegeneron Pharmaceuticals, Inc.
0.96%391.272.7%$362.55m
BIIBBiogen Inc.
-0.48%308.321.2%$348.13m
ALXNAlexion Pharmaceuticals, Inc.
0.85%108.511.9%$268.90m
VRTXVertex Pharmaceuticals Incorporated
-0.07%146.941.9%$232.57m
ALNYAlnylam Pharmaceuticals, Inc
0.87%133.4810.0%$194.84m
INCYIncyte Corporation
0.06%99.062.5%$179.35m
NKTRNektar Therapeutics
-2.80%48.366.1%$171.65m
ILMNIllumina, Inc.
-0.10%215.133.5%$154.37m
JUNOJuno Therapeutics, Inc.
1.82%61.4313.5%$140.13m
AAgilent Technologies, Inc.
0.54%69.061.5%$132.37m
SRPTSarepta Therapeutics, Inc.
0.18%56.3216.8%$115.83m
BLUEBluebird Bio, Inc.
0.70%168.3817.2%$115.23m

Company Profile

Ignyta, Inc. is a precision oncology biotechnology company that engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. It plans focus on two product candidates: entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors ROS1 and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related, or CDC7, protein kinase. The company was founded by Jonathan E. Lim on October 31, 2013 and is headquartered in San Diego, CA.